Pharmacokinetic investigation on a novel antitumour platinum compound in rabbit plasma by inductively coupled plasma mass spectrometry after intravenous administration

Drug Development and Industrial Pharmacy

Volumn 34, Issue 5, 2008, Pages 472-477

  Su, Qiang ^a,b   Liu, Qingfei ^b   Luo, Guoan ^c   Liu, Weiping ^d   Yu, Yao ^d   Wang, Yiming ^c   Bi, Kaishun ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Tsinghua University ^*  (China)

^c TSINGHUA UNIVERSITY   (China)

^d KUNMING INSTITUTE OF PRECIOUS METALS   (China)

Author keywords

Anticancer; ICP MS; Pharmacokinetics; Platinumcomplex; SM54111

Indexed keywords

3,5 DIISOPROPYLSALYLICCYCLOHEXANODIAMINOPLATINUM; PLATINUM DERIVATIVE; SM 54111;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; MASS SPECTROMETRY; NONHUMAN; RABBIT;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; INJECTIONS, INTRAVENOUS; MASS SPECTROMETRY; ORGANOPLATINUM COMPOUNDS; RABBITS;

EID: 45849130939     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701662560     Document Type: Article

References (30)

1. Alberts, D. S., & Fanta, P. T. (1997). In vitro phase II. Comparision of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother. Pharmacol., 39, 493-497.
2. Beauchemin, D. (2004). Inductively coupled plasma mass spectrometry. Anal. Chem., 76, 3395-3416.
3. Bernard, D., & Claudie, M. (2002). Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hemat., 42, 317-325.
4. Bernard, R. A. (1989). Review of therapeutic trials of carboplatinum in lung cancer. Sem. Onco., 16, 27-33.
5. Draqovich, T., Mendelson, A., Hoos, J., & Lewis, S. K. (2003). A phase II trial of aroplatln (L-NDDP), a liposomal DACH - A preliminary report. Colorectal Cancer, 22, 582.
6. Farrell, N., & Quy, H. M. (1990). Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J. Med. Chem., 33, 2179-2184.
7. Guchelaar, H. J., & Uges, D. R. (1992). Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions. Pharmaceutical Research, 9, 808-811.
8. Han, I., Kim, O. J., Lee, G. Y., & Sung, Y. K. (2003). Enhanced antitumor activity of trans(+-)-1,2-Diaminocyclohexaneglutamatoplatinum(II) formulated with stealth liposome. Bioorgan. Med. Chem., 11, 5443-5447.
9. Ho, Y.-P., & Au-Yeung, S. C. F. (2003). Platinum-based anticancer agents: Innovative design strategies and biological perspectives. Med. Res. Rev., 23, 633-655.
10. Hoeschele, J. D., Showalter, H. D. H., Kraker, A. J., Elliott, W. L., Roberts, B. J., & Kampf, J. W. (1994). Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation. J. Med. Chem., 37, 2630-2636.
11. Kelland, L. R. (2000). Preclinical perspectives on platinum resistance. Drugs, 59, 1-8.
12. Kim, D.-K., Kim, H.-T., Cho, Y.-B., Kim, T.-S., & Kim, K. H. (1996). In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2- spiro-1?-cyclopentane]platinum(II). Anticancer Res., 16, 251-256.
13. Kizu, R., Higashi, S.-I., & Kidani, Y. (1993). Pharmacokinetics of (1R, 2R-diaminocyclohexane) oxalatoplatinum (II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother. Phalmacol., 31, 475-480.
14. Luigi, C., La Grotta, G., Infante, L., Passera, R., Arpicco, S., & Brusa, P. (2003). Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. Il. Farmaco., 58, 1333-1338.
15. Luo, F. R., & Wyrick, S. D., & Stephen, G. C. (1999). Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother. Pharmacol., 44, 19-28.
16. Lv, W., Guo, J., Li, J., & Wang, X. (2006). Preparation and pharmacokinetics in rabbits of breviscapine unilamellar vesicles. Drug Dev. Ind. Pharm., 32, 309-314.
17. Meibohm, B. (2002). Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci., 19, 18-31.
18. Miles, D. R., Mesfin, M., Mody, T. D., Stiles, M., Lee, J., Fiene, J., & Bernie Denis, G. W. B. (2007). Validation and use of three complementary analytical methods (LC-FLS, LC-MS/MS and ICP-MS) to evaluate the pharmacokinetics, biodistribution and stability of motexafin gadolinium in plasma and tissues. Anal. Bioanal. Chem. (DOI 10.1007/s00216-006-0414-5).
19. Morrison, J. G., White, P., McDougall S., Firth J. W., Woolfrey S. G., & Graham M. A. (2000). Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: Application to clinical pharmacokinetic studies with oxaliplatin. J. Pharmaceut. Biomed., 24, 1-10.
20. Motofumi, Y., Khokhar, A. R., Zhang, Y.-P., & Gerald, T. (1994). Kinetics of tissue disposition of cis-ammine/cyclohexylamine- dichloroplatinum(II) and cisplatin in mice bearing FSallC tumors. Cancer Chemoth. Pharm., 35(1), 38-44.
21. O'Dwyer, P. J. (2000). Clinical pharmacokinetics and administration of established platinum drugs. Drugs, 59(Suppl.), 19-27.
22. Saito, T., & Manabe, Y. S. H. (1995). Ototoxicity of the new platinum anticancer agent TRK-710 in comparison with cisplatin. Otorhinolaryngol. Relat. Spec., 57(5), 235-255.
23. Shimakura, J., Fujimoto, K., Komuro, S., & Nakano, M. (2002). Long-term disposition of a novel lipophilic platinum complex SM-11355 in dog after intrahepatic arterial administration: Highly sensitive detection of platinum and radioactivity. Xenobiotica, 32(5), 399-409.
24. Smith, C. J., Wilson, I. D., Abou-Shakra, F., Payne, R., Parry, T. C., & Peta Sinclair, A. D. W. R. (2003). A comparison of the quantitative methods for the analysis of the platinum-containing anticancer drug {cis-[Amminedichloro(2-methylpyridine)]-platinum(II)} (ZD0473) by HPLC coupled to eithera triple quadrupole mass spectrometer or an inductively coupled plasma mass spectrometer. Anal. Chem., 75, 1463-1469.
25. Uehar, T., Watanabe, H., Itoh, F., Inoue, S., Koshid, H., Nakamura, M., & Yamate, J. (2005). Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: A comparative study with cisplatin in rats. Arch. Toxicol., 79, 451-460.
26. Van der Welink, J., & Pechstein, B. W. V. (1999). Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection. J. of Chromatography B., 675, 107-111.
27. Wang, T., Wu, J., Hartman, R., & Jia, X. (2000). A multi-element ICP-MS survey method as an alternative to the heavy metals limit test for pharmaceutical materials. J. Pharmaceut. Biomed., 23, 867-890.
28. Wong, E. (1999). Current status of platinum-based antitumor drugs. Chem. Rev., 99, 2451-2466.
29. Yamad, K. Kato, N., Takagi, A., & Koi, M. (2005). One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): Determination of platinum-DNA adducts in cells treated with platinum(II) complexes. Anal. Bioanal. Chem., 382, 1702-1707.
30. Yu, Y. (2006). Study of a novel antitumour platinum compound: Kunming, China. Institute of Precious Metal[D].